vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Iridium Communications Inc. (IRDM). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $219.1M, roughly 1.3× Iridium Communications Inc.). Iridium Communications Inc. runs the higher net margin — 9.9% vs -45.7%, a 55.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 1.9%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 4.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Iridium Communications Inc. is a publicly traded American company headquartered in McLean, Virginia, United States. Iridium operates the Iridium satellite constellation, a system of 80 satellites: 66 are active satellites and the remaining fourteen function as in-orbit spares. Iridium Satellites are used for worldwide voice and data communication from handheld satellite phones, satellite messenger communication devices and integrated transceivers, as well as for two-way satellite messaging se...
GH vs IRDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $219.1M |
| Net Profit | $-128.5M | $21.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 23.2% |
| Net Margin | -45.7% | 9.9% |
| Revenue YoY | 39.4% | 1.9% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $219.1M | ||
| Q4 25 | $281.3M | $212.9M | ||
| Q3 25 | $265.2M | $226.9M | ||
| Q2 25 | $232.1M | $216.9M | ||
| Q1 25 | $203.5M | $214.9M | ||
| Q4 24 | $201.8M | $213.0M | ||
| Q3 24 | $191.5M | $212.8M | ||
| Q2 24 | $177.2M | $201.1M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $-128.5M | $24.9M | ||
| Q3 25 | $-92.7M | $37.1M | ||
| Q2 25 | $-99.9M | $22.0M | ||
| Q1 25 | $-95.2M | $30.4M | ||
| Q4 24 | $-111.0M | $36.3M | ||
| Q3 24 | $-107.8M | $24.4M | ||
| Q2 24 | $-102.6M | $32.3M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 23.2% | ||
| Q4 25 | -43.0% | 25.9% | ||
| Q3 25 | -37.3% | 30.9% | ||
| Q2 25 | -45.9% | 23.2% | ||
| Q1 25 | -54.6% | 28.1% | ||
| Q4 24 | -62.4% | 24.5% | ||
| Q3 24 | -61.3% | 25.8% | ||
| Q2 24 | -56.8% | 21.7% |
| Q1 26 | — | 9.9% | ||
| Q4 25 | -45.7% | 11.7% | ||
| Q3 25 | -35.0% | 16.4% | ||
| Q2 25 | -43.0% | 10.1% | ||
| Q1 25 | -46.8% | 14.2% | ||
| Q4 24 | -55.0% | 17.1% | ||
| Q3 24 | -56.3% | 11.5% | ||
| Q2 24 | -57.9% | 16.1% |
| Q1 26 | — | — | ||
| Q4 25 | $-1.01 | $0.24 | ||
| Q3 25 | $-0.74 | $0.35 | ||
| Q2 25 | $-0.80 | $0.20 | ||
| Q1 25 | $-0.77 | $0.27 | ||
| Q4 24 | $-0.90 | $0.30 | ||
| Q3 24 | $-0.88 | $0.21 | ||
| Q2 24 | $-0.84 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | — |
| Total Assets | $2.0B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | $96.5M | ||
| Q3 25 | $580.0M | $88.5M | ||
| Q2 25 | $629.1M | $79.3M | ||
| Q1 25 | $698.6M | $50.9M | ||
| Q4 24 | $525.5M | $93.5M | ||
| Q3 24 | $585.0M | $159.6M | ||
| Q2 24 | $933.7M | $63.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $1.8B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $1.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-99.3M | $462.6M | ||
| Q3 25 | $-354.5M | $450.5M | ||
| Q2 25 | $-305.5M | $473.6M | ||
| Q1 25 | $-250.8M | $518.4M | ||
| Q4 24 | $-139.6M | $576.6M | ||
| Q3 24 | $-60.1M | $663.8M | ||
| Q2 24 | $-1.6M | $786.7M |
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $2.5B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.5B | $2.7B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.80× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.05× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 13.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $108.6M | ||
| Q3 25 | $-35.4M | $100.8M | ||
| Q2 25 | $-60.3M | $129.6M | ||
| Q1 25 | $-62.7M | $61.1M | ||
| Q4 24 | $-64.5M | $104.8M | ||
| Q3 24 | $-51.1M | $118.6M | ||
| Q2 24 | $-94.0M | $81.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $75.1M | ||
| Q3 25 | $-45.8M | $79.2M | ||
| Q2 25 | $-65.9M | $108.9M | ||
| Q1 25 | $-67.1M | $36.5M | ||
| Q4 24 | $-83.4M | $80.5M | ||
| Q3 24 | $-55.3M | $100.0M | ||
| Q2 24 | $-99.1M | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 35.3% | ||
| Q3 25 | -17.3% | 34.9% | ||
| Q2 25 | -28.4% | 50.2% | ||
| Q1 25 | -33.0% | 17.0% | ||
| Q4 24 | -41.3% | 37.8% | ||
| Q3 24 | -28.9% | 47.0% | ||
| Q2 24 | -55.9% | 34.2% |
| Q1 26 | — | 13.7% | ||
| Q4 25 | 9.9% | 15.7% | ||
| Q3 25 | 3.9% | 9.5% | ||
| Q2 25 | 2.4% | 9.5% | ||
| Q1 25 | 2.2% | 11.4% | ||
| Q4 24 | 9.4% | 11.4% | ||
| Q3 24 | 2.2% | 8.7% | ||
| Q2 24 | 2.9% | 6.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.37× | ||
| Q3 25 | — | 2.71× | ||
| Q2 25 | — | 5.90× | ||
| Q1 25 | — | 2.01× | ||
| Q4 24 | — | 2.88× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 2.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IRDM
| Voice and data | $57.4M | 26% |
| IoT data (2) | $46.0M | 21% |
| Government | $39.5M | 18% |
| Government service revenue (5) | $27.6M | 13% |
| Subscriber equipment | $20.2M | 9% |
| Hosted payload and other data service (4) | $14.8M | 7% |
| Broadband (3) | $12.2M | 6% |
| Commercial | $1.3M | 1% |
